SCHEMBL15765227

SCHEMBL15765227

CC(=O)c1ccc(-c2cccc3c2OC(CNC(=O)OC(C)(C)C)C3)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.38
▸ DRD2 P14416 2/20 0.36
▸ ACKR3 P25106 1/20 0.36
▸ PRKDC P78527 1/20 0.35
▸ PGR P06401 1/20 0.35
▸ PRKAB2 O43741 1/20 0.34
▸ PRKAG1 P54619 1/20 0.34
▸ PRKAA2 P54646 1/20 0.34
▸ PRKAA1 Q13131 1/20 0.34
▸ PRKAG3 Q9UGI9 1/20 0.34
▸ PRKAG2 Q9UGJ0 1/20 0.34
▸ PRKAB1 Q9Y478 1/20 0.34
▸ EPHX2 P34913 1/20 0.33
▸ RORC P51449 5/20 0.33
▸ GPR52 Q9Y2T5 1/20 0.33
▸ CKS1B P61024 1/20 0.32
▸ SKP1 P63208 1/20 0.32
▸ SKP2 Q13309 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32
▸ DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17974444 0.81 PRKDC (0.39) PRKDCPGRPRKAB2PRKAG1PRKAA2
SCHEMBL15764954 0.81 F10 (0.35) NAMPTDRD2ACKR3PGRRORC
SCHEMBL15765047 0.80 PGR (0.37) NAMPTDRD2ACKR3PGRRORC
SCHEMBL15765226 0.80 PRKAB2 (0.48) PRKDCPGRPRKAB2PRKAG1PRKAA2
SCHEMBL17961180 0.78 PRKAB2 (0.38) PRKDCPGRPRKAB2PRKAG1PRKAA2
SCHEMBL15764934 0.78 DRD2 (0.43) NAMPTDRD2PRKAB2PRKAG1PRKAA2
SCHEMBL17974445 0.77 DRD2 (0.42) NAMPTDRD2EPHX2RORCACACB
SCHEMBL5793270 0.77 DRD2 (0.46) NAMPTDRD2EPHX2RORCACACB
SCHEMBL15765225 0.76 MAPT (0.35) NAMPTPRKDC
SCHEMBL17961281 0.76 MAPT (0.35) NAMPTPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 — — US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 — — US disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 NAMPT 2985/4885DRD2 2012/4885ACKR3 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback